Modulation of visceral hyperalgesia by morphine and cholecystokinin from the rat rostroventral medial medulla

Pain

Volumn 104, Issue 1-2, 2003, Pages 93-101

  Friedrich, Ann E ^a   Gebhart, G F ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

2,4,6 trinitrobenzenesulfonic acid; Colon distension; Colon inflammation

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ANALGESIC AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; DEVAZEPIDE; MORPHINE SULFATE; TRINITROBENZENESULFONIC ACID;

ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG POTENTIATION; ELECTROMYOGRAPHY; HYPERALGESIA; MALE; MEDULLA OBLONGATA; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; VISCERAL PAIN;

EID: 0037824384     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(02)00469-4     Document Type: Article

References (71)

1. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulin, and CCK antagonists in nociception. Pain. 39:1989;307-328.
2. Basbaum A.I. Spinal mechanisms of acute and persistent pain. Reg Anesth Pain Med. 24:1999;59-67.
3. Benoliel J.J., Bourgoin S., Mauborgne A., Legrand J.C., Hamon M., Cesselin F. Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation. Neurosci Lett. 124:1991;204-207.
4. Bowker R.M., Dilts R.P. Distribution of mu opioid receptors in the nucleus raphe magnus and nucleus gigantocellularis: a quantitative autoradiographic study. Neurosci Lett. 88:1988;247-252.
5. Brink T., Mason P. Raphe magnus neurons respond to noxious colorectal stimulation. J Neurophysiol. 2003;(in press).
6. Coutinho S.V., Urban M.O., Gebhart G.F. Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia. Pain. 78:(1):1998;59-69.
7. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
8. Dickenson A.H., Oliveras J.L., Besson J.M. Role of the nucleus raphe magnus in opiate analgesia as studied by the microinjection technique in the rat. Brain Res. 170:1979;95-111.
9. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature. 264:1976;568-570.
10. Dourish C.T., Hill D.R. Classification and function of CCK receptors. Trends Pharmacol Sci. 8:1987;207-208.
11. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Mol Brain Res. 6:1989;31-37.
12. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
13. Friedrich A.E., Gebhart G.F. Cholecystokinin mediates morphine antinociception in the rostral ventromedial medulla. Soc Neurosci Abstr. 26:2000;661.
14. Friedrich A.E., Gebhart G.F. Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat. J Pharmacol Exp Ther. 292:2000;538-544.
15. Friedrich A.E., Gebhart G.F. Sources of spinal cholecystokinin. Soc Neurosci Abstr. 25:1999;1434.
16. Gall C., Lauterborn J., Burks D., Seroogy K. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res. 403:1987;403-408.
17. Gebhart G.F., Sengupta J.N. Evaluation of visceral pain. Gaginella T.S. Handbook of methods in gastrointestinal pharmacology. 1996;359-373 CRC Press, Boca Raton, FL.
18. Guan Y., Terayama R., Dubner R., Ren K. Plasticity in excitatory amino acid receptor-mediated descending pain modulation after inflammation. J Pharmacol Exp Ther. 300:2002;513-520.
19. Hawranko A.A., Smith D.J. Stress reduces morphine's antinociceptive potency: dependence upon spinal cholecystokinin processes. Brain Res. 824:1999;251-257.
20. Heinricher M.M., McGaraughty S., Tortorici V. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol. 85:(1):2001;280-286.
21. Hokfelt T., Zhang X., Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci. 17:1994;22-30.
22. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain: each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 98:2000;585-598.
23. Hurley R.W., Hammond D.L. The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci. 20:2000;1249-1259.
24. Iadarola M.J., Brady L.S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioural parameters and opioid receptor binding. Pain. 35:1988;313-326.
25. Innis R.B., Snyder S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA. 77:1980;6917-6921.
26. Itoh S., Katsuura G., Maeda Y. Cauerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol. 80:1982;421-425.
27. Jensen T.S., Yash T.L. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedical medulla in the rat. Brain Res. 363:1986;99-113.
28. Ji R.R., Zhang Q., Law P.-Y., Low H.H., Elde R., Hokfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci. 15:1995;8156-8166.
29. Kalra A., Urban M.O., Sluka K.A. Blockade of opioid receptors in rostral ventral medulla prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS). J Pharmacol Exp Ther. 298:2001;257-263.
30. Kellstein D.E., Price D.D., Mayer D.J. Cholecystokinin and its antagonist lorglumide respectively attenuate and facilitate morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurons. Brain Res. 540:1991;302-306.
31. Kovelowski C.J., Ossipov M.H., Sun H., Lai J., Malan T.P., Porreca F. Supraspinal cholecystokinin may drive tonic descending facilitation mechanisms to maintain neuropathic pain in the rat. Pain. 87:2000;265-273.
32. Lucas G.A., Alster P., Brodin E., Wiesenfeld-Hallin Z. Differential release of cholecystokinin by morphine in rat spinal cord. Neurosci Lett. 245:1998;13-16.
33. MacKenzie J. Symptoms and their interpretation. 1909;Shaw, London.
34. Mantyh P.W., Hunt S.P. Evidence for cholecystokinin-like immunoreactive neurons in the rat medulla oblongata which project to the spinal cord. Brain Res. 291:1984;49-54.
35. Mason P. Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. Ann Rev Neurosci. 24:2001;737-777.
36. Mercer L.D., Beart P.M. Histochemistry in rat and spinal cord with an antibody directed at the cholecystokinin (A) receptor. Neurosci Lett. 4:1997;97-100.
37. Miki K., Zhou Q.-Q., Guo W., Guan Y., Terayama R., Dubner R., Ren K. Changes in gene expression and neuronal phenotype in brain stem pain modulatory circuitry after inflammation. J Neurophysiol. 87:2002;750-760.
38. Millan M.J. Descending control of pain. Prog Neurobiol. 66:2002;355-474.
39. Mitchell J.M., Lowe D., Fields H.L. The contribution of the rostral ventromedial medulla to the antinociceptive effects of systemic morphine in restrained and unrestrained rats. Neuroscience. 87:1998;123-133.
40. Moran T.H., Robinson M.S., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. 362:1986;175-179.
41. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:1989;795-803.
42. Ness T.J., Gebhart G.F. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res. 450:(1-2):1988;153-169.
43. Ness T.J., Randich A., Gebhart G.F. Further behavioral evidence that colorectal distension is a 'noxious' visceral stimulus in rats. Neurosci Lett. 131:1991;113-116.
44. Noguchi K., Dubner R., Ruda M.A. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience. 46:1992;561-570.
45. O'Neill M.F., Dourish C.T., Iversen S.D. Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology. 28:1989;243-249.
46. Paxinos G., Watson C. The rat brain in stererotaxic coordinates. 2nd ed. 1986;Academic Press, New York, NY.
47. Porreca F., Ossipov M.H., Gebhart G.F. Chronic pain and medullary descending facilitation. Trends Neurosci. 25:2002;319-325.
48. Rehfeld J.F., Hansen H.F. Cholecystokinin and gastrin peptides in the nervous system: post-translational processing of the precursors. De Belleroche J., Dockray G.J. Cholecystokinin (CCK) in the nervous system. 1984;31-40 Ellis Horwood, Chichester.
49. Ruda M.A., Iadarola M.J., Cohen L.V., Young W.S. In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. Proc Natl Acad Sci USA. 8:1988;622-626.
50. Saito A., Sankaran H., Goldfine I.D., Williams J.A. Cholecystokinin receptors in brain: characterization and distribution. Science. 208:1980;1155-1156.
51. Stanfa L., Dickenson A., Xu X.-J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci. 15:1994;65-66.
52. Stanfa L.C., Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br J Pharmacol. 108:1993;967-973.
53. Stanfa L., Dickenson A. Spinal opioid systems in inflammation. Inflamm Res. 44:1995;231-241.
54. Stein C., Cabot P.J., Schafer M. Peripheral opioid analgesia: mechanisms and clinical implications. Stein C.,. Opioids in pain control. 1999;96-108 Cambridge University Press, Cambridge.
55. Stengaard-Pederson K., Larsson L.-I. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system. Peptides. 2:(1):1981;3-19.
56. Suh H.H., Tseng L.F. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by β-endorphin and morphine administered intracerebroventricularly in mice. Eur J Pharmacol. 179:1990;329-339.
57. Suh H.H., Collins K.A., Tseng T. Intrathecal cholecystokinin octapeptide attenuates the antinociception and release of immunoreactive metenkephalin induced by intraventricular 66-endorphin in the rat. Neuropeptides. 21:1992;131-137.
58. Tang J., Chou J., Iadarola M., Yang H.Y.T., Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology. 23:1984;715.
59. Tseng L.F., Collins K.A. Cholecystokin in administered intrathecally selectively antagonizes intracerebroventricular β-endorphin-induced tail-flick inhibition in the mouse. J Pharmacol Exp Ther. 260:1992;1086-1092.
60. Urban M.O., Gebhart G.F. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci USA. 96:1999;7687-7692.
61. Valverde O., Maldonado R., Fournie-Zaluski M.C., Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther. 270:1994;77-88.
62. Watkins L.R., Kinscheck I.B., Mayer D.J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science. 224:1984;395-396.
63. Watkins L.R., Kinscheck I.B., Mayer D.J. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res. 327:1985;169-180.
64. Watkins L.R., Kinschenck I.B., Kaufman E.F.S., Miller J., Frenk H., Mayer D.J. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327:1985;181-190.
65. Wiesenfeld-Hallin Z., Duranti R. Intrathecal cholecystokinin interacts with morphine but not substance P in modulating the nociceptive flexor reflex in the rat. Peptides. 8:1987;152-158.
66. Wiesenfeld-Hallin Z., Lucas G.A., Alster P., Xu X.-J., Hokfelt T. Cholecytokinin/opioid interactions. Brain Res. 848:1999;78-89.
67. Woodruff G.N., Hill D.R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides. 19:1991;45-56.
68. Xu X.-J., Puke M.J.C., Verge V.M.K., Wisenfeld-Hallin Z., Hughes J., Hokfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett. 152:1993;129-132.
69. Xu X.-J., Alster P., Wu W.-P., Hao J.-X., Wiesenfeld-Hallin Z. Increased level of cholecystokinin in cerbrospinal fluid is associated with chronic pain-like behavior in spinally injured rats. Peptides. 22:2001;1305-1308.
70. Zhang X., Lucas A., Elde R., Wiesenfeld-Hallin Z., Hokfelt T. Effect of morphine and cholecystokinin and μ-opioid receptor-like immunoreactivities in rat spinal dorsal horn neurons after peripheral axotomy and inflammation. Neuroscience. 95:2000;197-207.
71. B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol. 234:1993;147-154.